William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Conference call with management will be held on April 16 at 2 pm hosted by JPMorgan. Webcast LinkStay Ahead of the Market: Discover ...

American Century Companies Inc. raised its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.1% during the ...

Xencor (XNCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse pipeline ...